This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Accounting for the differences and understanding the appropriate way to model the marketplace for biosimilars, as opposed to generics, may have significant consequences for economic analyses in the context of litigation. In this article, we identify some of those differences and their implications.
1 in 4 people globally are already affected by NCDs. By 2030, NCDs will cause 55 million deaths per year under ‘business as usual.’1,2 Effective...
Given the complexity of diagnosing rare disease patients, identifying real-world prevalence rates is difficult, as ranges from academic literature are often...
CRA is a proud sponsor of the event covering divisional patent strategies, denigration, Article 102, enforcement, mergers, distribution, as well as...
Tunahan Kirabali is a speaker during the webinar about sex and gender differences in the Alzheimer’s patient journey highlighting implications for clinical...
